With respect to anti-CCL2 mAbs, in an ovarian cancer xenograft mouse model, the anti-human CCL2 IgG1 human mAb Carlumab was found to enhance the efficacy of chemotherapies paclitaxel and carboplatin [65]. Here, CCL2 is linked to ovarian cancer.